





Supplemental Figure 1. Median Progression Free survival for CLL patients at MD Anderson on BRUIN trial



Supplemental Figure 2. Correlation between baseline features and progression free survival of CLL patients (n=25).




Supplemental Figure 3. Baseline mutant BTK shows higher risk of PD and acquiring second site BTK mutation.




Supplemental Figure 4. Venetoclax and APR-246 addition to pirtobrutinib augment apoptotic response at time of PD.







A



B




C




Supplemental Figure 5. Pharmacogenomic and pharmacological profiling in PBMCs at time of Disease progression .


A



B



C



END